Humacyte Inc HUMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HUMA is a good fit for your portfolio.
News
-
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
-
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
-
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
-
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
-
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
-
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
-
Humacyte Shares Rise After FDA Grants Priority Review to Vascular Trauma Treatment
-
Humacyte Gets Speedy FDA Review of Bioengineered Tissue in Vascular Trauma
Trading Information
- Previous Close Price
- $3.92
- Day Range
- $3.93–4.17
- 52-Week Range
- $1.97–5.55
- Bid/Ask
- $4.07 / $4.09
- Market Cap
- $490.62 Mil
- Volume/Avg
- 463,031 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 185
- Website
- https://www.humacyte.com
Comparables
Valuation
|
Metric
|
HUMA
|
NVCT
|
IMVT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 30.00 | 8.68 | 5.86 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
HUMA
NVCT
IMVT
Financial Strength
|
Metric
|
HUMA
|
NVCT
|
IMVT
|
|---|---|---|---|
Quick Ratio | 4.36 | 2.74 | 21.56 |
Current Ratio | 4.52 | 2.75 | 22.14 |
Interest Coverage | −16.62 | — | — |
Quick Ratio
HUMA
NVCT
IMVT
Profitability
|
Metric
|
HUMA
|
NVCT
|
IMVT
|
|---|---|---|---|
Return on Assets (Normalized) | −54.76% | −85.22% | −43.33% |
Return on Equity (Normalized) | −146.92% | −115.93% | −47.83% |
Return on Invested Capital (Normalized) | −77.45% | −120.14% | −52.69% |
Return on Assets
HUMA
NVCT
IMVT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cvqchkjyx | Gptlx | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jpwcxnrl | Xqrbwq | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Llgmhjv | Tymzvkg | $98.1 Bil | |
MRNA
| Moderna Inc | Zlqgschn | Frzm | $42.2 Bil | |
ARGX
| argenx SE ADR | Svdkhvmj | Wxmc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hmhzxwf | Tytym | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ckcgdjtm | Ffmrrtn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mjkkwykh | Mbrwxv | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mfvkvpmxbc | Pmvzl | $12.5 Bil | |
INCY
| Incyte Corp | Yqlhmdlzz | Gtvkxs | $11.7 Bil |